ContraVir Pharmaceuticals Stock Price, Forecast & Analysis (NASDAQ:CTRV) Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ContraVir Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Today's Range N/A50-Day Range$2.53MA: $3.11▼$3.5852-Week Range N/AVolume145,741 shsAverage Volume432,822 shsMarket Capitalization$2.34 millionP/E RatioN/ADividend YieldN/ABeta1.16 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ContraVir Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections. It engages in the development of TXL, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B; and CRV431, a novel drug candidate for the treatment of chronic HBV infection. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CTRV Previous Symbol CUSIPN/A CIK1583771 Webhttp://www.contravir.com/ Phone732-902-4000Debt Debt-to-Equity RatioN/A Current Ratio0.55 Quick Ratio0.55Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.80 per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net Income$-9,450,000.00 Net MarginsN/A Return on Equity-4,810.77% Return on Assets-130.14%Miscellaneous Employees14 Outstanding Shares800,000Market Cap$2.34 million Next Earnings DateN/A OptionableNot Optionable Receive CTRV News and Ratings via Email Sign-up to receive the latest news and ratings for CTRV and its competitors with MarketBeat's FREE daily newsletter. ContraVir Pharmaceuticals (NASDAQ:CTRV) Frequently Asked Questions What is ContraVir Pharmaceuticals' stock symbol? ContraVir Pharmaceuticals trades on the NASDAQ under the ticker symbol "CTRV." When did ContraVir Pharmaceuticals' stock split? How did ContraVir Pharmaceuticals' stock split work? ContraVir Pharmaceuticals shares reverse split before market open on Tuesday, May 29th 2018. The 1-8 reverse split was announced on Thursday, May 24th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 28th 2018. An investor that had 100 shares of ContraVir Pharmaceuticals stock prior to the reverse split would have 13 shares after the split. How were ContraVir Pharmaceuticals' earnings last quarter? ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) posted its earnings results on Friday, May, 13th. The biopharmaceutical company reported ($1.12) EPS for the quarter, topping the consensus estimate of ($1.80) by $0.68. View ContraVir Pharmaceuticals' Earnings History. What is the consensus analysts' recommendation for ContraVir Pharmaceuticals? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ContraVir Pharmaceuticals in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ContraVir Pharmaceuticals. Has ContraVir Pharmaceuticals been receiving favorable news coverage? Media stories about CTRV stock have trended very negative recently, according to InfoTrie Sentiment. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. ContraVir Pharmaceuticals earned a news sentiment score of -3.2 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for ContraVir Pharmaceuticals. Who are some of ContraVir Pharmaceuticals' key competitors? Some companies that are related to ContraVir Pharmaceuticals include Neurotrope (NTRP), Uluru (ULUR), NeuroVive Pharmaceutical (NEVPF), Novus Therapeutics (NVUS), Acura Pharmaceuticals (ACUR), Tetraphase Pharmaceuticals (TTPH), Capricor Therapeutics (CAPR), BENITEC BIOPHAR/S (BNTC), Sonoma Pharmaceuticals (SNOA), Trillium Therapeutics (TRIL), Reliv International (RELV), Rexahn Pharmaceuticals (REXN), Genprex (GNPX), X T L Biopharmaceuticals (XTLB) and Cyclacel Pharmaceuticals (CYCC). What other stocks do shareholders of ContraVir Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other ContraVir Pharmaceuticals investors own include Advaxis (ADXS), Alliqua Biomedical (ALQA), Sorrento Therapeutics (SRNE), Anavex Life Sciences (AVXL), Madrigal Pharmaceuticals (MDGL), Synergy Pharmaceuticals (SGYP), Protalix Biotherapeutics (PLX), Palatin Technologies (PTN), CytRx (CYTR) and Corbus Pharmaceuticals (CRBP). Who are ContraVir Pharmaceuticals' key executives? ContraVir Pharmaceuticals' management team includes the folowing people: Dr. Robert T. Foster BSc (Pharm), Pharm.D., Ph.D., CEO, Pres, Chief Scientific Officer & Director (Age 61)Dr. John Z. Sullivan-Bolyai, Part-Time Consultant (Age 71)Mr. John T. Cavan, Chief Financial Officer (Age 61)Sharen Pyatetskaya, Director of Investor Relations How big of a company is ContraVir Pharmaceuticals? ContraVir Pharmaceuticals has a market capitalization of $0.00. ContraVir Pharmaceuticals employs 14 workers across the globe.View Additional Information About ContraVir Pharmaceuticals. What is ContraVir Pharmaceuticals' official website? The official website for ContraVir Pharmaceuticals is http://www.contravir.com/. How can I contact ContraVir Pharmaceuticals? ContraVir Pharmaceuticals' mailing address is 399 THORNALL STREET FIRST FLOOR, EDISON NJ, 08837. The biopharmaceutical company can be reached via phone at 732-902-4000 or via email at [email protected] MarketBeat Community Rating for ContraVir Pharmaceuticals (NASDAQ CTRV)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 202 (Vote Outperform)Underperform Votes: 132 (Vote Underperform)Total Votes: 334MarketBeat's community ratings are surveys of what our community members think about ContraVir Pharmaceuticals and other stocks. Vote "Outperform" if you believe CTRV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTRV will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/13/2019 by MarketBeat.com StaffFeatured Article: What is channel trading?